David Sinclair· PhD
The longevity biotech is accelerating toward the clinic after uncovering a promising age-reprogramming therapy years sooner than expected.
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
The longevity biotech is accelerating toward the clinic after uncovering a promising age-reprogramming therapy years sooner than expected.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
I think within our lifetimes we'll see the first one the coma patients are waiting for this we're working on starting a clinical trial hopefully within the next 18 months